FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318539193> ?p ?o ?g. }

• W4318539193 endingPage "i900" @default.
• W4318539193 startingPage "i900" @default.
• W4318539193 abstract "Abstract Background The A.U.R.O.R.A. database is an Italian multicenter retrospective cohort of patients with ulcerative colitis (UC) treated with the first biological drugs (infliximab biosimilar- IFX-B, adalimumab-ADA, golimumab-GOL, vedolizumab-VDZ) approved in Italy after patent expire of IFX-originator. In a previous published study,1 we showed similar efficacy among all drugs according to the rigorous outcome of 1-year “continuous clinical remission” (CCR). In this study, we focused only on steroid-dependent UC, by comparing all drugs to each other and to patients treated with steroids followed by azatioprine (AZA) monotherapy. Methods All consecutive patients with steroid-dependent UC, treated with IFX-B, ADA, GOL or VDZ after their approval in 2014-2019, were followed-up for 1 year or until drug discontinuation for relapse or adverse events. All drugs were compared to each other and to steroid-dependent patients treated with steroids + AZA in 2006-2014. A propensity score analysis was performed to balance differences at baseline. The primary endpoint was the 1-year CCR, defined as steroid-free clinical remission with Mayo partial score ≤2 (with no bleeding), without any clinical relapse or treatment optimization after the first remission was achieved, and without drug withdrawal due to adverse events. Treatment optimization was defined as the addition of systemic/topical steroids, oral/topical mesalazine or any dose escalation of biologics Results 370 patients (IFX-B=62, ADA=68, GOL=56, VDZ=100, AZA 84) with steroid-dependent UC were included. No significant differences were found among each biological drug according to the 1-year CCR primary end-point (34%, 29%, 30%, 39%, respectively). In patients naive to immunesuppressors and biologics (n= 17, 25, 24 10, 79, respectively), AZA showed significantly higher rate of CCR (68%) than each biological drug (35%, 44%, 33%, 60%; p=0.000 for each comparison) or all biologics as a whole (41%; p=0.012). Adverse events occurred significantly less frequently with ADA (8%) than IFX (29%), GOL (20%) and AZA (26%) in the overall population, but were similar across all drugs in the naive population. Discontinuation for adverse events occurred more frequently (p&lt;0.05) with both IFX-B (16%) and AZA (14%) than ADA (3%), GOL (4%), and VDZ (1%) in the overall population, but not in the naive population (18%, 15%, 4%, 4%, 0%, respectively). Conclusion In steroid-dependent UC, anti-TNF-alpha agents and VDZ were equally effective at 1 year according to the concept of CCR. AZA still appears an effective first-line strategy in the biological era. 1Cassinotti A. et al. Eur J Gastroenterol Hepatol. 2022;34:1238-46. Guided Poster Session" @default.
• W4318539193 created "2023-01-31" @default.
• W4318539193 creator A5008990417 @default.
• W4318539193 creator A5010322302 @default.
• W4318539193 creator A5010467819 @default.
• W4318539193 creator A5020832351 @default.
• W4318539193 creator A5022353696 @default.
• W4318539193 creator A5023617515 @default.
• W4318539193 creator A5027528495 @default.
• W4318539193 creator A5027638735 @default.
• W4318539193 creator A5030033986 @default.
• W4318539193 creator A5031176212 @default.
• W4318539193 creator A5031234325 @default.
• W4318539193 creator A5031330585 @default.
• W4318539193 creator A5031512636 @default.
• W4318539193 creator A5031656098 @default.
• W4318539193 creator A5043037433 @default.
• W4318539193 creator A5056522563 @default.
• W4318539193 creator A5059347689 @default.
• W4318539193 creator A5068692273 @default.
• W4318539193 creator A5069499370 @default.
• W4318539193 creator A5072523035 @default.
• W4318539193 creator A5080233829 @default.
• W4318539193 creator A5080846388 @default.
• W4318539193 creator A5091562515 @default.
• W4318539193 date "2023-01-30" @default.
• W4318539193 modified "2023-09-26" @default.
• W4318539193 title "P771 Biologics versus azathioprine in steroid-dependent ulcerative colitis: results from the A.U.R.O.R.A. database" @default.
• W4318539193 doi "https://doi.org/10.1093/ecco-jcc/jjac190.0901" @default.
• W4318539193 hasPublicationYear "2023" @default.
• W4318539193 type Work @default.
• W4318539193 citedByCount "0" @default.
• W4318539193 crossrefType "journal-article" @default.
• W4318539193 hasAuthorship W4318539193A5008990417 @default.
• W4318539193 hasAuthorship W4318539193A5010322302 @default.
• W4318539193 hasAuthorship W4318539193A5010467819 @default.
• W4318539193 hasAuthorship W4318539193A5020832351 @default.
• W4318539193 hasAuthorship W4318539193A5022353696 @default.
• W4318539193 hasAuthorship W4318539193A5023617515 @default.
• W4318539193 hasAuthorship W4318539193A5027528495 @default.
• W4318539193 hasAuthorship W4318539193A5027638735 @default.
• W4318539193 hasAuthorship W4318539193A5030033986 @default.
• W4318539193 hasAuthorship W4318539193A5031176212 @default.
• W4318539193 hasAuthorship W4318539193A5031234325 @default.
• W4318539193 hasAuthorship W4318539193A5031330585 @default.
• W4318539193 hasAuthorship W4318539193A5031512636 @default.
• W4318539193 hasAuthorship W4318539193A5031656098 @default.
• W4318539193 hasAuthorship W4318539193A5043037433 @default.
• W4318539193 hasAuthorship W4318539193A5056522563 @default.
• W4318539193 hasAuthorship W4318539193A5059347689 @default.
• W4318539193 hasAuthorship W4318539193A5068692273 @default.
• W4318539193 hasAuthorship W4318539193A5069499370 @default.
• W4318539193 hasAuthorship W4318539193A5072523035 @default.
• W4318539193 hasAuthorship W4318539193A5080233829 @default.
• W4318539193 hasAuthorship W4318539193A5080846388 @default.
• W4318539193 hasAuthorship W4318539193A5091562515 @default.
• W4318539193 hasBestOaLocation W43185391931 @default.
• W4318539193 hasConcept C126322002 @default.
• W4318539193 hasConcept C197934379 @default.
• W4318539193 hasConcept C203092338 @default.
• W4318539193 hasConcept C2776207728 @default.
• W4318539193 hasConcept C2776760755 @default.
• W4318539193 hasConcept C2777138892 @default.
• W4318539193 hasConcept C2777575956 @default.
• W4318539193 hasConcept C2778715236 @default.
• W4318539193 hasConcept C2779134260 @default.
• W4318539193 hasConcept C2779174533 @default.
• W4318539193 hasConcept C2780132546 @default.
• W4318539193 hasConcept C2780479503 @default.
• W4318539193 hasConcept C2781290027 @default.
• W4318539193 hasConcept C535046627 @default.
• W4318539193 hasConcept C71924100 @default.
• W4318539193 hasConcept C90924648 @default.
• W4318539193 hasConceptScore W4318539193C126322002 @default.
• W4318539193 hasConceptScore W4318539193C197934379 @default.
• W4318539193 hasConceptScore W4318539193C203092338 @default.
• W4318539193 hasConceptScore W4318539193C2776207728 @default.
• W4318539193 hasConceptScore W4318539193C2776760755 @default.
• W4318539193 hasConceptScore W4318539193C2777138892 @default.
• W4318539193 hasConceptScore W4318539193C2777575956 @default.
• W4318539193 hasConceptScore W4318539193C2778715236 @default.
• W4318539193 hasConceptScore W4318539193C2779134260 @default.
• W4318539193 hasConceptScore W4318539193C2779174533 @default.
• W4318539193 hasConceptScore W4318539193C2780132546 @default.
• W4318539193 hasConceptScore W4318539193C2780479503 @default.
• W4318539193 hasConceptScore W4318539193C2781290027 @default.
• W4318539193 hasConceptScore W4318539193C535046627 @default.
• W4318539193 hasConceptScore W4318539193C71924100 @default.
• W4318539193 hasConceptScore W4318539193C90924648 @default.
• W4318539193 hasIssue "Supplement_1" @default.
• W4318539193 hasLocation W43185391931 @default.
• W4318539193 hasOpenAccess W4318539193 @default.
• W4318539193 hasPrimaryLocation W43185391931 @default.
• W4318539193 hasRelatedWork W2006826205 @default.
• W4318539193 hasRelatedWork W2042655884 @default.
• W4318539193 hasRelatedWork W2105263940 @default.
• W4318539193 hasRelatedWork W2138584845 @default.
• W4318539193 hasRelatedWork W2152399325 @default.

• next